Platelet Dysfunction Diseases and Conditions: Clinical Implications and Considerations
Introduction Platelet diseases and dysfunction are taught early in medical school to all future physicians. Understanding of the coagulation cascade and hemostatic mechanisms has allowed for targeted pharmacological therapies that have been significantly impactful in clinical practice. Platelets are an early participant in hemostasis physiologically and under pathophysiological states. Methods A review of literature involving platelet disfunction. Results Various presentations of platelet diseases and dysfunction challenge clinicians and require a firm understanding of normal platelet function, drugs that mediate or modulate platelet effectiveness, and nonpharmacologic etiologies of platelet diseases and dysfunction with corresponding best practice treatment approaches. Conclusion This review summarizes normal and abnormal states associated with platelets and treatment strategies..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Advances in therapy - 37(2020), 9 vom: 29. Juli, Seite 3707-3722 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaye, Alan D. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Hemostasis |
| Anmerkungen: |
© Springer Healthcare Ltd., part of Springer Nature 2020 |
|---|
| doi: |
10.1007/s12325-020-01453-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC211891699X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC211891699X | ||
| 003 | DE-627 | ||
| 005 | 20230504163045.0 | ||
| 007 | tu | ||
| 008 | 230504s2020 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-020-01453-4 |2 doi | |
| 035 | |a (DE-627)OLC211891699X | ||
| 035 | |a (DE-He213)s12325-020-01453-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
| 100 | 1 | |a Kaye, Alan D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platelet Dysfunction Diseases and Conditions: Clinical Implications and Considerations |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Healthcare Ltd., part of Springer Nature 2020 | ||
| 520 | |a Introduction Platelet diseases and dysfunction are taught early in medical school to all future physicians. Understanding of the coagulation cascade and hemostatic mechanisms has allowed for targeted pharmacological therapies that have been significantly impactful in clinical practice. Platelets are an early participant in hemostasis physiologically and under pathophysiological states. Methods A review of literature involving platelet disfunction. Results Various presentations of platelet diseases and dysfunction challenge clinicians and require a firm understanding of normal platelet function, drugs that mediate or modulate platelet effectiveness, and nonpharmacologic etiologies of platelet diseases and dysfunction with corresponding best practice treatment approaches. Conclusion This review summarizes normal and abnormal states associated with platelets and treatment strategies. | ||
| 650 | 4 | |a Hemostasis | |
| 650 | 4 | |a Platelet disfunction | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 4 | |a Thrombotic thrombocytopenic purpura | |
| 700 | 1 | |a Jeha, George M. |4 aut | |
| 700 | 1 | |a Moll, Vanessa |4 aut | |
| 700 | 1 | |a Ward, Ceressa T. |4 aut | |
| 700 | 1 | |a Watson, Matthew R. |4 aut | |
| 700 | 1 | |a Wynn, John Thomas |4 aut | |
| 700 | 1 | |a Hockstein, Maxwell A. |4 aut | |
| 700 | 1 | |a Hall, Kevin M. |4 aut | |
| 700 | 1 | |a Viswanath, Omar |4 aut | |
| 700 | 1 | |a Urits, Ivan |4 aut | |
| 700 | 1 | |a Prabhakar, Amit |4 aut | |
| 700 | 1 | |a Cornett, Elyse M. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 1984 |g 37(2020), 9 vom: 29. Juli, Seite 3707-3722 |w (DE-627)168085585 |w (DE-600)632651-1 |w (DE-576)482252200 |x 0741-238X |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:9 |g day:29 |g month:07 |g pages:3707-3722 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12325-020-01453-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 9 |b 29 |c 07 |h 3707-3722 | ||